Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Otorhinolaryngology and Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan
In Vivo. 2021 Mar-Apr;35(2):1253-1259. doi: 10.21873/invivo.12376.
BACKGROUND/AIM: For recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune checkpoint inhibitors are impractical for platinum-intolerant patients. Herein, the efficacy and safety of paclitaxel and cetuximab combination therapy in R/M SCCHN were evaluated.
In this retrospective study, paclitaxel (80 mg/m) and cetuximab (400 mg/m loading dose followed by 250 mg/m weekly) were administered in 28-day cycles on days 1, 8, and 15.
Thirty-eight patients were treated. The overall response and disease control rates of first-line therapy were 43% and 79%, respectively, while those of second-line and later therapies were 20% and 90%, respectively. The median progression-free and overall survival were 5.3 and 12.5 months, respectively. All adverse events were manageable, including grade 3/4 neutropenia and anaemia affecting 8-13% of patients.
Paclitaxel and cetuximab combination therapy may be suitable for treating R/M SCCHN.
背景/目的：对于复发性/转移性头颈部鳞状细胞癌（R/M SCCHN），含有铂类抗癌药物和免疫检查点抑制剂的常用方案对于铂类不耐受的患者来说并不实用。本文旨在评估紫杉醇和西妥昔单抗联合治疗 R/M SCCHN 的疗效和安全性。
在这项回顾性研究中，患者在 28 天的周期中接受紫杉醇（80mg/m）和西妥昔单抗（首剂量 400mg/m，随后每周 250mg/m）治疗，于第 1、8 和 15 天给药。
共 38 例患者接受了治疗。一线治疗的总缓解率和疾病控制率分别为 43%和 79%，二线及以后治疗的总缓解率和疾病控制率分别为 20%和 90%。中位无进展生存期和总生存期分别为 5.3 个月和 12.5 个月。所有不良事件均可管理，包括 8-13%的患者出现 3/4 级中性粒细胞减少和贫血。
紫杉醇和西妥昔单抗联合治疗可能适用于治疗 R/M SCCHN。
